Amelioration of nedaplatin-induced nephrotoxicity by continuous infusion in rats

Journal of Toxicologic Pathology

Volumn 20, Issue 3, 2007, Pages 141-147

  Uehara, Takeki ^a   Tsuchiya, Noriko ^a   Torii, Mikinori ^a   Yamate, Jyoji ^b   Maruyama, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b Osaka City University   (Japan)

Author keywords

Amelioration; Continuous infusion; Nedaplatin; Nephrotoxicity; Rat

Indexed keywords

EID: 35548944473     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.20.141     Document Type: Article

References (28)

1. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, and Saijo N. Phase II study of (glycolato-O,O) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol. 26: 393-396. 1990.
2. Ota K, Wakui A, Majima H, Niitani H, Inuyama Y, Ogawa M, Ariyoshi Y, Yoshida O, Taguchi T, and Kimura I. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho. 19: 855-861. 1992 (In Japanese).
3. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, and Ota K. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. Gan To Kagaku Ryoho. 19: 483-488. 1992 (In Japanese).
4. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, and Ota K. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Gan To Kagaku Ryoho. 19: 871-877. 1992.
5. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, and Aso Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol. 31: 187-192. 1992.
6. Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, and Ota M. Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho. 19: 695-701. 1992 (In Japanese).
7. Ota K. Nedaplatin. Gan To Kagaku Ryoho. 23: 379-387. 1996 (In Japanese).
8. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, and Maruyama T. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol. 79: 451-460. 2005.
9. Chervenick PA, Boggs DR, Marsh JC, Cartwright GE, and Wintrobe MM. Quantitative studies of blood and bone marrow neutrophils in normal mice. Am J Physiol. 215: 353-360. 1968.
10. Goldstein RS and Mayor GH. Minireview. The nephrotoxicity of cisplatin. Life Sci. 32: 685-690. 1983.
11. Arany I and Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 23: 460-464. 2003.
12. Hartmann JT and Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 4: 889-901. 2003.
13. Posner MR, Skarin AT, Clark J, and Endo TJ. Phase I study of continuous-infusion cisplatin. Cancer Treat Rep. 70: 847-850. 1986.
14. Bozzino JM, Prasad V, and Koriech OM. Avoidance of renal toxicity by 24-hour infusion of cisplatin. Cancer Treat Rep. 65: 351-352. 1981.
15. Cornelison TL and Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 50: 147-158. 1993.
16. Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, and Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 52: 13-18. 2003.
17. Ali BH and Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol. 44: 1173-1183. 2006.
18. Meyer KD and Madias NE. Cisplatin nephrotoxicity. Miner Electrolyte Metab. 20: 201-213. 1994.
19. Taguchi T, Nazneen A, Abid MR, and Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol. 148: 107-121. 2005.
20. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. 50: 219-244. 1966.
21. Daugaard G and Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol. 25: 1-9. 1989.
22. Smith PHS and Taylor DM. Distribution and retention of the antitumour agent 195M-PT-cis-dichlorodiammineplatinum (II) in man. J Nucl Med. 15: 349-351. 1974.
23. Litterst CL, LeRoy AF, and Guarino AM. Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals. Cancer Treat Rep. 63: 1485-1492. 1979.
24. Fichtinger-Schepman AM, Vendrik CP, van Dijk-Knijnenburg WC, de Jong WH, van der Minnen AC, Claessen AM, van der Velde-Visser SD, de Groot G, Wubs KL, Steerenberg PA, Schornagel, JH, and Berends F. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma. Cancer Res. 49: 2862-2867. 1989.
25. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, and Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 48: 761-770. 1995.
26. Townsend DM, Deng M, Zhang L, Lapus MG, and Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 14: 1-10. 2003.
27. Kawai Y, Taniuchi S, Okahara S, Nakamura M, and Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull. 28: 1385-1388. 2005.
28. Sugeno K, Mizojiri K, Okabe H, Esumi Y, Takaichi M, and Okada Y. Studies on the disposition of a new antineoplastic agent, cis-diammine(glycolato)platinum (254-S) (I) Distribution and excretion of platinum in rats. Iyakuhin Kenkyu. 22: 231-242. 1991 (In Japanese).